AXSM Q1 2024 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M-20.7% YoY

Gross Profit

$69M91.6% margin

Operating Income

-$67M-89.7% margin

Net Income

-$68M-91.1% margin

EPS (Diluted)

$-1.44

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$54M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$546M

Total Liabilities

$402M

Stockholders' Equity

$144M

Cash & Equivalents

$331M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$95M	-20.7%
Gross Profit	$69M	$87M	-21.1%
Operating Income	-$67M	-$6M	-955.5%
Net Income	-$68M	-$11M	-509.4%

Revenue Segments

Product

$74M99%

Royalty

$903,0001%

Geographic Segments

UNITED STATES

$73M99%

Non-US

$903,0001%